Overview

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safest dose of topotecan when given in a high dose before a stem cell transplant; topotecan will be given with melphalan.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
GlaxoSmithKline
National Cancer Institute (NCI)
Treatments:
Melphalan
Topotecan